NYSTATIN AND TRIAMCINOLONE ACETONIDE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, immune response, and vasodilation.
| Metabolism | Nystatin is not absorbed systemically and is excreted unchanged in feces. Triamcinolone acetonide is metabolized in the liver via CYP3A4, primarily to 6β-hydroxytriamcinolone and other metabolites. |
| Excretion | Nystatin: primarily excreted unchanged in feces via bile (>90%); negligible renal excretion (<1%). Triamcinolone acetonide: primarily hepatically metabolized; conjugated metabolites excreted renally (70%) and via bile (20% fecal). Systemic absorption of triamcinolone acetonide after topical application is minimal (<1%). |
| Half-life | Nystatin: not systemically absorbed; terminal half-life not applicable. Triamcinolone acetonide: after intramuscular injection, terminal half-life is approximately 2-5 hours; after topical application, minimal systemic absorption precludes meaningful half-life determination. |
| Protein binding | Nystatin: negligible binding due to lack of systemic absorption. Triamcinolone acetonide: approximately 68% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Nystatin: not applicable (no systemic absorption). Triamcinolone acetonide: Vd approximately 1-2 L/kg after IM injection, reflecting extensive tissue distribution. |
| Bioavailability | Nystatin: oral bioavailability negligible (<5%) due to poor absorption from GI tract; intended for local effect only. Triamcinolone acetonide: topical bioavailability unknown but minimal due to poor percutaneous absorption (less than 1% of dose enters systemic circulation); after IM injection, bioavailability is 100%. |
| Onset of Action | Nystatin: oral suspension for oral candidiasis: clinical effect within 24-48 hours; topical for cutaneous candidiasis: improvement within 24-72 hours. Triamcinolone acetonide: topical anti-inflammatory effect begins within hours of application; maximal effect by 3-5 days. |
| Duration of Action | Nystatin: treatment typically requires 24-48 hours of application after lesions heal; duration depends on adequacy of therapy. Triamcinolone acetonide: topical effects last 6-12 hours after a single application; with occlusion, effect may be prolonged. |
Apply thin layer to affected area twice daily for 2-4 weeks. Topical only.
| Dosage form | OINTMENT |
| Renal impairment | No adjustment required. |
| Liver impairment | No adjustment required. |
| Pediatric use | Apply thin layer to affected area twice daily. Safety and efficacy not established for children <2 years; limited data for older children. |
| Geriatric use | No specific adjustment; use caution due to skin thinning and potential for systemic absorption. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Breastfeeding | Nystatin is not absorbed systemically; triamcinolone acetonide has minimal absorption from topical use. With normal topical use, excretion into breast milk is negligible. However, if applied to large areas or under occlusion, systemic absorption may increase. M/P ratio not available. Considered compatible with breastfeeding if used sparingly on small areas. |
| Teratogenic Risk |
■ FDA Black Box Warning
None
| Common Effects | Hyperglycemia |
| Serious Effects |
["Hypersensitivity to nystatin, triamcinolone acetonide, or any component of the formulation","Fungal infections other than those caused by Candida species","Viral infections of the skin (e.g., herpes simplex, vaccinia, varicella)"]
| Precautions | ["Prolonged use may lead to overgrowth of nonsusceptible organisms including bacteria and fungi","Avoid use in patients with known hypersensitivity to any component","In case of sensitization or irritation, treatment should be discontinued","Systemic absorption of topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and hyperglycemia; use with caution in pediatric patients and over large areas or occlusive dressings"] |
Loading safety data…
| Topical nystatin and triamcinolone acetonide: nystatin is not absorbed; triamcinolone acetonide has low systemic absorption from topical use. However, corticosteroids are generally considered to have potential fetal risk (cleft palate, growth restriction) if used systemically in first trimester. Topical use is considered low risk, but avoid prolonged use on large areas. FDA pregnancy category C; use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required for topical use. If used chronically on large areas, monitor maternal blood pressure and blood glucose (steroid effect). Fetal monitoring not indicated. |
| Fertility Effects | No known adverse effects on fertility from topical nystatin/triamcinolone acetonide. Systemic corticosteroids may affect ovulation, but topical use has negligible systemic levels. |